---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-249192"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:15:47.828592+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Madrigal raises ~$472M in stock/warrant offering to fund resmetirom launch prep

## Summary
- Offering of 1,248,098 shares at $151.69 and 2,048,098 pre-funded warrants at $151.6899 per warrant.
- Estimated net proceeds ~$472M (excluding underwriter's option); closing expected Oct 3, 2023.
- Proceeds for clinical/commercial activities for potential U.S. launch of resmetirom and general corporate purposes.
- Underwriters have 30-day option to purchase up to 494,429 additional shares.
- Directors and executive officers subject to 60-day lock-up without underwriter consent.

## SEC filing metadata
- accession: 0001193125-23-249192
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312523249192/0001193125-23-249192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312523249192/d485845d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-249192
- JSON: https://secwatch.observer/filing/0001193125-23-249192.json
- Plain text: https://secwatch.observer/filing/0001193125-23-249192.txt

## Key facts
- Material Agreements
  MADRIGAL PHARMACEUTICALS, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein valued at approximately $472.0 million (effective 2023-09-28).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, as representative of the several underwriters named therein
  - Value: approximately $472.0 million
  - Effective: 2023-09-28
  source text: Madrigal Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312523249192/0001193125-23-249192-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.